ROHHAD treatment – Patient Worthy

Source: https://pixabay.com/en/horizontal-bathroom-scale-weight-162952/

This Drug Would Target the Heart of Genetic Obesity

Post author:Sarah Lau
Post published:June 20, 2017
Post category:Rare Disease ROHHAD

Rhythm Pharmaceuticals is currently developing a melanocrotin-4 (MC4) receptor therapy called setmelanotide for the treatment of obesity and related disorders caused by genetic defects. This therapy could potentially be used to…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More